Alliance Pharma PLC Appointment of NED and SID (4957O)

TIDMAPH

RNS Number : 4957O

Alliance Pharma PLC

01 February 2023

 
 For immediate release   1 February 2023 
 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

Appointment of Non-Executive Director and Senior Independent Director

Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce the appointment of Martin Sutherland as a new independent Non-Executive Director and Richard Jones, a Non-Executive Director since 2019, as Senior Independent Director to strengthen the Board and support the delivery of the Company's growth strategy.

Martin, who will join the Board with immediate effect, is a senior executive with over 30 years' experience in global businesses. He is currently a NED at FTSE listed Forterra plc and Reliance acsn ltd. Forterra is a leading UK manufacturer of essential clay and concrete building products. Martin joined the Board of Forterra in 2017 and sits on the Nomination, Remuneration, Audit, and Risk & Sustainability committees. Reliance acsn ltd is a privately held specialist cyber security business, a company which he joined in 2020 as CEO and helped to drive a doubling of revenues in two years. Martin stepped down as CEO to become NED in January 2023.

Martin was CEO of De La Rue plc between 2014 and 2019 and previously held various roles at Detica plc, becoming Managing Director in 2008 on its acquisition by BAE Systems plc. Martin has a proven track record of delivering growth through new product innovation, market diversification and international expansion. We believe that Martin's experience will bring a new perspective to complement the strong consumer healthcare knowledge already present on the Board.

Following its annual review, the Board has decided to appoint Richard Jones, current NED and Chair of Audit & Risk Committee, as Senior Independent Director with immediate effect. Richard is CFO of Medica Group plc, the UK's leading teleradiology provider, and has been on the Alliance Board since 1 January 2019.

David Cook, Chair of Alliance, said :

"I am delighted to welcome Martin Sutherland to the Board and look forward to his contribution to support the delivery of our growth strategy. Martin will bring significant additional expertise from his experience as a company director and in senior executive leadership roles. The Board will also benefit from his 30 years' experience in managing global businesses and delivering growth.

"I am also pleased to appoint Richard Jones as our first Senior Independent Director. Richard will help support and expand our stakeholder engagement programme, building on his extensive experience in capital markets and leveraging his strong networks with shareholders."

The following information is disclosed pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies.

Mr Martin Conrad Sutherland, aged 54, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships    Directorships in the past five 
  Forterra plc             years: 
  Reliance acsn Limited    De La Rue plc 
                           19 Bennerley Road Limited 
                           The International Currency Association 
                           Limited 
 

Mr Sutherland does not hold any ordinary shares of 1 pence each in the Company.

For further information:

 
 Alliance Pharma plc                              + 44 (0)1249 466966 
 Cora McCallum, Head of Investor Relations 
  & Corporate Communications                      + 44 (0)1249 705168 
 [e-mail] 
 
                                                      + 44 (0)20 7466 
 Buchanan                                                        5000 
 Mark Court / Hannah Ratcliff 
 [e-mail] 
 
                                                      + 44 (0)20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Freddie Barnfield / Duncan 
  Monteith 
 Corporate Broking: James Black 
 
                                                      + 44 (0)20 7597 
 Investec Bank plc                                               5970 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADBGDBBGXDGXB

(END) Dow Jones Newswires

February 01, 2023 02:00 ET (07:00 GMT)